Development of a Novel Soluble Epoxide Hydrolase Inhibitor As a Strategy for Treating Neuropathic Pain in Patients with SCI
Latest Information Update: 17 Mar 2025
At a glance
- Drugs EC 5026 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors EicOsis
- 13 Mar 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 13 Mar 2025 Planned primary completion date changed from 1 Nov 2025 to 1 Jun 2026.
- 13 Mar 2025 Planned initiation date changed from 1 Dec 2024 to 1 Apr 2025.